# XBiotech Inc.: Form 10-Q for the period ended Sep 30, 2016

- Company: [XBiotech Inc.](/companies/xbit.md) (CIK 1626878)
- Form: 10-Q
- Filed: 2016-11-14
- Accepted by EDGAR: Nov 14, 2016, 15:32 ET
- Period: 2016-09-30
- Accession: 0001171843-16-013213
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1626878/000117184316013213/f10q_111416p.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1626878/000117184316013213/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2016-07-01 to 2016-09-30 | $9.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2016-01-01 to 2016-09-30 | $28.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2016-07-01 to 2016-09-30 | $12.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-01-01 to 2016-09-30 | $36.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 9 months, 2016-01-01 to 2016-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-07-01 to 2016-09-30 | −$12.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-01-01 to 2016-09-30 | −$36.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-07-01 to 2016-09-30 | −$0.38 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2016-01-01 to 2016-09-30 | −$1.12 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2016-01-01 to 2016-09-30 | −$33.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2016-01-01 to 2016-09-30 | $4.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-09-30 | $46.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-09-30 | $48.8m | us-gaap:AssetsCurrent |
| Total assets | at 2016-09-30 | $78.3m | us-gaap:Assets |
| Current liabilities | at 2016-09-30 | $6.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-09-30 | $6.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-09-30 | $71.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 23,009 characters.

### MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Overview

XBiotech is a clinical-stage biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of different diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization technologies or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. While primarily focused on bringing our lead product candidate to market, we have also developed a proprietary True Human™ monoclonal antibody discovery platform and manufacturing system.

We have never been profitable and, as of September 30, 2016, we had an accumulated deficit of $167.0 million. We had net losses of $12.5 million and $36.4 million for three months and nine months ended September 30, 2016, respectively, compared to $10.7 million and $25.6 million for three months and nine months ended September 30, 2015, respectively. We expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we add personnel and continue to operate as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so. As of September 30, 2016, we had 106 employees.

### Recent Events:

XBiotech's marketing authorization application for Xilonix™ for the treatment of colorectal cancer remains on schedule to possibly achieve a decision in 2016 by the European Medicines Agency (EMA).

The phase III colorectal cancer study being conducted under a Fast Track designation from the FDA remains on-track. This study is randomized 2:1 with patients receiving Xilonix™ or placebo plus best supportive care with a primary endpoint of overall survival.

The phase 2 study of Xilonix™ in subjects with Pyoderma Gangrenosum has been completed and data is being finalized.

The Company’s Phase I/II clinical study assessing 514G3 as a treatment of *Staphylococcus Aureus* Bacteremia remains on course with potential enrollment completion by end of year.

The Company is currently preparing the new manufacturing facility to produce registration batches of product. Data from these manufacturing runs will be submitted to EMA to support approval of the new facility. The current plan is to submit that filing at the end of Q1 2017.The facility will not be placed into service until approval has been received.

### Revenues

To date, we have not generated any revenue. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize our lead product candidate, Xilonix™, or any other product candidate we may advance in the future.

### Research and Development Expenses

Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, share-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.

Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through September 30, 2016, we have recorded total research and development expenses, including share-based compensation, of $129.9 million. Our total research and development expenses for the three months and nine months ended September 30, 2016 were $9.8 million and $28.8 million, respectively, compared to $9.7 million and $20.9 million for the three months and nine months ended September 30, 2015, respectively. Share-based compensation accounted for $0.6 million and $1.7 million for the three months and nine months ended September 30, 2016, respectively, compared to $0.7 million and $1.7 million for the three months and nine months ended September 30, 2015, respectively.

Research and development expenses, as a percentage of total operating expenses for the three months and nine months ended September 30, 2016 were 78% and 79%, respectively, compared to 90% and 82% for the three months and nine months ended September 30, 2015, respectively. The percentages, *excluding* share-based compensation, for the three months and nine months ended September 30, 2016 were 81% and 84%, respectively, compared to 91% and 87% for the three months and nine months ended September 30, 2015, respectively.

Based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success as well as commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.

Increased research and development costs for the nine months ended September 30, 2016 were anticipated and primarily due to Phase II and Phase III studies related to XBiotech’s research and development programs in Xilonix™ and 514G3 as well as laboratory and manufacturing supplies purchased for general manufacturing activities and for the new facility.

Due to the fact that our drug candidates are in the early stage of development, we cannot estimate anticipated completion dates and when we might receive material net cash inflows from our research and development projects.

### General and Administrative Expenses

General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, professional fees for legal services, and public relations expenses. Our total general and administration expenses for the three months and nine months ended September 30, 2016 were $2.7 million and $7.5 million, respectively, compared to $1.0 million and $4.5 million for the three months and nine months ended September 30, 2015, respectively. Stock-based compensation accounted for $0.6 million and $2.3 million for the three months and nine months ended September 30, 2016, respectively, compared to $0.2 million and $1.7 million for the three months and nine months ended September 30, 2015, respectively.

### Critical Accounting Policies

Our Management’s Discussion and Analysis of our Financial Condition and Results of Operations is based on our financial statements, which have been prepared in conformity with generally accepted accounting principles in the United States, or US GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and expenses incurred during the reported periods.

We base estimates on our historical experience, known trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in the notes to our financial statements appearing in this prospectus, we believe that the following accounting policies are the most critical to understanding and evaluating our reported financial results.

### Share-Based Compensation

Share-based awards are measured at fair value at each grant date. We recognize share-based compensation expenses ratably over the requisite service period of the option award.

### Determination of the Fair Value of Share-Based Compensation Grants

The determination of the fair value of share-based compensation arrangements is affected by a number of variables, including estimates of the fair value of our common stock, expected stock price volatility, risk-free interest rate and the expected life of the award. We value stock options using the Black-Scholes option-pricing model, which was developed for use in estimating the fair value of traded options that are fully transferable and have no vesting restrictions. Black-Scholes and other option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. If we made different assumptions, our share-based compensation expenses, net loss, and net loss per common share could be significantly different. Prior to our IPO in April 2015, we issued common stock for cash consideration to new investors. We believe that such transactions represent the best evidence of fair value of our common stock. After our IPO, we determine that the fair value of common stock equal to the closing price of the Company’s common stock as reported by NASDAQ on the option grant date.

The following summarizes the assumptions used for estimating the fair value of share-based compensation for the stock options granted during the periods indicated:

|  | Three Months Ended September 30, 2016 |  |  | 2015 |  |  | Nine Months Ended September 30, 2016 |  |  | 2015 |  |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Dividend yield |  | - |  |  | - |  |  |  |  |  |  |  |
| Expected volatility |  | 70% |  |  | 66% |  | 65% | - | 70% | 66% | - | 71% |
| Risk-free interest rate | 1.09% | - | 1.60% | 1.75% | - | 1.93% | 1.09% | - | 1.82% | 1.07% | - | 2.42% |
| Expected life (in years) | 5.26 | - | 10.00 |  | 10 |  | 5 | - | 10 | 3 | - | 10 |
| Weighted-average grant date fair value per share |  | $8.50 |  |  | $16.91 |  |  | $7.09 |  |  | $17.99 |  |

We have assumed no dividend yield because we do not expect to pay dividends in the foreseeable future, which is consistent with our past practice. The risk-free interest rate assumption is based on observed interest rates for U.S. Treasury securities with maturities consistent with the expected life of our stock options. The expected life represents the period of time the stock options are expected to be outstanding and is based on the simplified method when the stock option includes “plain vanilla” terms. Under the simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the agreement term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock options. For stock options that did not include “plain vanilla” terms we used the contractual life of the stock option as the expected life. Such stock options consisted primarily of options issued to our board of directors that were immediately vested at issuance. Due to the lack of sufficient trading history for our common stock, expected volatility is based on historical volatilities for publicly traded stock of comparable companies over the estimated expected life of the stock options.

We based our estimate of pre-vesting forfeitures, or forfeiture rate, on historical forfeiture rates. We apply the estimated forfeiture rate to the total estimated fair value of the awards, as derived from the Black-Scholes model, to compute the share-based compensation expenses, net of pre-vesting forfeitures, to be recognized in our consolidated statements of operations.

### Results of Operations

### Revenue

We did not record any revenue during the three months and nine months ended September 30, 2016 and 2015.

### Expenses

#### Research and Development

Research and Development costs are summarized as follows (in thousands):

|  | Three Months Ended September 30, 2016 | 2015 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $2,437 | $1,581 | $856 | 54% |
| Laboratory and manufacturing supplies | 2,217 | 1,141 | 1,076 | 94% |
| Clinical trials and sponsored research | 3,598 | 5,059 | (1,461) | (29)% |
| Share-based compensation | 565 | 701 | (136) | (19)% |
| Other | 957 | 1,249 | (292) | (23)% |
| Total | $9,774 | $9,731 | $43 | 0% |

|  | Nine Months Ended September 30, 2016 | 2015 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $6,274 | $4,558 | $1,716 | 38% |
| Laboratory and manufacturing supplies | 5,755 | 3,180 | 2,575 | 81% |
| Clinical trials and sponsored research | 11,911 | 8,463 | 3,448 | 41% |
| Share-based compensation | 1,749 | 1,677 | 72 | 4% |
| Other | 3,112 | 3,018 | 94 | 3% |
| Total | $28,801 | $20,896 | $7,905 | 38% |

We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.

Research and development expenses increased to $9.8 million for the three months ended September 30, 2016 compared to $9.7 million for the three months ended September 30, 2015. Research and development expenses increased by 38% to $28.8 million for the nine months ended September 30, 2016 compared to $20.9 million for the nine months ended September 30, 2015.

The three months difference in research and development expenses was mainly due to a $1.5 million decrease in clinical trial activities, related to a Europe trial started in 2015 and completed in early 2016, offset by a continued increase in laboratory and manufacturing supplies expense due to an increase in manufacturing activities as well as manufacturing supplies purchased for the new facility. Salaries and related expenses continued to increase due to the growing size of the workforce.

Compared to the nine months ended September 30, 2015, the research and development expense increase in the nine months ended September 30, 2016 was primarily caused by substantial growth in laboratory and manufacturing operations which led to an increase in purchased supplies. Labor costs also increased due to a rise in current employees’ salaries as well as an increase in the Research and Development workforce from 58 to 80. Clinical trial expenses increased due to an expansion of clinical sites globally.

#### General and Administrative

General and administrative costs are summarized as follows (in thousands):

|  | Three Months Ended September 30, 2016 | 2015 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $445 | $235 | $210 | 89% |
| Patent filing expense | 135 | 172 | (37) | (22)% |
| Share-based compensation | 561 | 185 | 376 | 203% |
| Professional fees | 1,063 | 58 | 1,005 | 1733% |
| Other | 481 | 433 | 48 | 11% |
| Total | $2,685 | $1,083 | $1,602 | 148% |

|  | Nine Months Ended September 30, 2016 | 2015 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $1,358 | $844 | $514 | 61% |
| Patent filing expense | 488 | 655 | (167) | (25)% |
| Share-based compensation | 2,291 | 1,678 | 613 | 37% |
| Professional fees | 1,923 | 480 | 1,443 | 301% |
| Other | 1,461 | 885 | 576 | 65% |
| Total | $7,521 | $4,542 | $2,979 | 66% |

General and administrative expenses increased 148% to $2.7 million for the three months ended September 30, 2016 compared to $1.1 million for the three months ended September 30, 2015. General and administrative expenses increased 66% to $7.5 million for the nine months ended September 30, 2015 compared to $4.5 million for the nine months ended September 30, 2015.

The three months increase was primarily related to a $1.0 million increase in fees related to commercialization activities in Europe. The increase in stock–based compensation expense was due to the grant of stock options to board members in September 2016. The increase is also attributable to salaries and related expenses, which continued to increase due to the onboarding of new employees in 2016.

The nine months increase was principally due to a $0.5 million salary increase from growth of our workforce, and a $1.4 million increase in the fees related to commercialization activities in Europe. Share-based compensation also increased by $0.6 million due to the grant of stock options to outside board members in March and September 2016. Other reasons for increases included insurance, travel expense and recruiting activities.

### Other income

The following table summarizes other income (in thousands):

|  | Three Months Ended September 30, 2016 | 2015 | Nine Months Ended September 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Foreign exchange gain(loss) | $(25) | $78 | $(41) | $(155) |
| Total | $(25) | $78 | $(41) | $(155) |

22

Other income consists primarily of a $25 thousand foreign exchange loss for the three months ended September 30, 2016, compared to a $78 thousand gain for the three months ended September 30, 2015. Also, foreign exchange loss for the nine months ended September 30, 2016 was $41 thousand, compared to $155 thousand for the nine months ended September 30, 2015.

### Liquidity and Capital Resources

Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.

Since our inception on March 22, 2005 through September 30, 2016, we have funded our operations principally through the sales of equity securities in private and public transactions, which have provided aggregate cash proceeds of approximately $287.9 million. The following table summarizes our sources and uses of cash (in thousands):

| Net cash (used in) provided by: | Nine Months Ended September 30, 2016 | 2015 |
| --- | ---: | ---: |
| Operating activities | $(33,214) | $(22,613) |
| Investing activities | (11,946) | (6,646) |
| Financing activities | 866 | 77,468 |
| Effect of foreign exchange rate on cash and cash equivalents | 36 | 142 |
| Net change in cash and cash equivalents | $(44,258) | $48,351 |

During the nine months ended September 30, 2016 and 2015, our operating activities used net cash of $33.2 million and $22.6 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The increase in net loss from operations for the nine months ended September 30, 2016 as compared to the nine months ended September 30, 2015 was mainly due to increases in clinical trial activities, labor cost and manufacturing supplies.

During the nine months ended September 30, 2016 and 2015, our investing activities used net cash of $11.9 million and $6.6 million, respectively. We spent approximately $3.0 million more on the construction of new facilities during the nine months ended September 30, 2016 compared to the nine months ended September 30, 2015. We also spent approximately $2.3 million more on scientific equipment during the nine months ended September 30, 2016 compared to the nine months ended September 30, 2015.

During the nine months ended September 30, 2016 and 2015, our financing activities provided net cash proceeds of $0.9 million and $77.5 million, respectively. During the nine months ended September 30, 2016, employees exercised stock options to purchase a total of 164,686 shares of common stock. In April 2015, we sold an aggregate of 4,000,000 shares of our common stock at a price of $19.00 per share and received IPO proceeds of $76.0 million and incurred offering costs of $5.4 million, which consisted of underwriters’ commission as well as direct incremental legal, accounting and other professional service fees related to our IPO.

On September 26, 2016, we entered into a Common Stock Sales Agreement with H.C. Wainwright & Co. LLC which establishes an at-the-market equity program pursuant to which we may offer and sell shares of our common stock, no par value per share, from time to time as set forth in the Sales Agreement. The Sales Agreement provides for the sale of shares of our Common Stock having an aggregate offering price of up to $50,260,000. Sales of Shares under the Sales Agreement will be made pursuant to the registration statement on Form S-3, which was declared effective by the U.S. Securities and Exchange Commission on September 1, 2016, and a related Prospectus Supplement filed with the SEC on September 26, 2016.

### Contractual Obligations and Commitments

On January 12, 2008, we entered a lease agreement to lease our facility in Austin, Texas. On September 15, 2010, we entered into a second lease agreement to lease additional space in Austin, Texas. On March 20, 2014, we extended the lease for an additional 21 months on the same terms and rental rates as the current lease. Rent expense was $181 thousand and $164 thousand for the three months ended September 30, 2016 and 2015, respectively. On February 28, 2015, we extended the lease for another 4 years. The future minimum lease payments are as follows as of September 30, 2016 (in thousands):

| Contractual Obligations | Total | Less than 1 Year | 1 - 3 Years | More than 3 years |
| --- | ---: | ---: | ---: | ---: |
| Operating facility leases | $1,235 | $455 | $645 | $— |
| Total contractual obligations | $1,235 | $455 | $645 | $— |

Concerning the new manufacturing facility, the total estimated future payment to our general contractor is $1.2 million and to purchase new equipment is $5.6 million. The last payment is expected to occur in Q4 2016.

### Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

## Market risk

As filed, 238 characters.

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company currently engages in no hedging activities.

## Controls and procedures

As filed, 1,787 characters.

### Management's Evaluation of our Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.

### Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 837 characters.

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2015. Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our Common Stock. Additional risks not currently known or currently material to us may also harm our business.

Filed Nov 14, 2016.
Source: SEC EDGAR, the filing index for accession 0001171843-16-013213. Last ingested by Listed: Nov 14, 2026, 18:14 ET. No prices; not investment advice.
